GLAUCOMA 360
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
2
Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial
3
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
4
Retina Society 2026: Ocular syphilis, HIV co-infection, and RPR titers
5